Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Orrin "hatches plan"

This article was originally published in The Tan Sheet

Executive Summary

Sen. Orrin Hatch (R-Utah) announces his candidacy for the Republican Presidential nomination July 1 on CNN's Larry King Live. Rumors had been circulating earlier about his intentions (1"The Tan Sheet" June 28, In Brief)

You may also be interested in...



Hatch running for President?

Rumors are circulating that Sen. Orrin Hatch (R-Utah) will formally announce the week of June 28 his intention to run for the Republican Presidential nomination. Hatch has long played an active role in legislation dealing with the OTC and dietary supplement industries. A co-author of the Waxman/Hatch Drug Price Competition and Patent Term Restoration Act of 1984, he also was a principal player in the passage of the Dietary Supplement Health & Education Act in 1994. Hatch posed numerous questions to then-FDA Commissioner nominee Jane Henney, MD, and met with her during the nomination process. He also recently asked FDA, along with Sen. Tom Harkin (D-Iowa), about the agency's progress in creating dietary supplement GMPs

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090013

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel